HIV prevention trials halted on safety concerns

Polydex Pharmaceuticals has stopped two trials of a microbicide gel after a health organization involved in a trial found that it was linked to a higher risk of HIV infection. A second trial of the HIV therapy Ushercell was also halted in Nigeria due to the safety concerns. Researchers said they would conduct a detailed review.

"It was our hope that this product would have helped women in protecting themselves from HIV," says Dr. Lut Van Damme, principal investigator. "While the findings are unexpected and disappointing, we will learn scientifically important information from this trial that will inform future HIV prevention research."

- see the release

Suggested Articles

Galecto picked up $64 million to push its lead lung disease treatment toward an approval in Europe and fund midstage studies for its other programs.

The financing, which attracted support from Roche Venture Fund, sets Palladio up to test its vasopressin V2 receptor antagonist in a kidney disease.

A new atlas of 500,000 cardiac cells could help researchers better understand how a healthy heart operates—and what goes wrong in heart disease.